IMPACT OF BIOLOGICAL THERAPY ON BONE IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.14412/1995-4484-2014-669-677
Abstract
The paper gives the data currently available in the literature on the impact of biological agents (BA) on bone mineral density, metabolism, and remodeling in rheumatoid arthritis (RA). These agents, by virtue of their high efficacy, are widely used to treat patients with RA. Since localized and generalized bone resorption and destruction play a prominent role in its pathogenesis, an investigation of the effect of BA on bone may be of essential interest. Activated osteoclastogenesis occurs because of an interaction between the immune and bone systems under the influence of different proinflammatory cytokines. The inhibition of the latter has been ascertained to not only reduce joint inflammation, but also to prevent localized and generalized osteoporosis. This review discusses the results of these trials and the issues of further investigations.
About the Authors
P. S. Dydykina
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
Russian Federation
I. S. Dydykina
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
Russian Federation
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
Russian Federation
References
1. Насонов ЕЛ, Насонова ВА. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. 290 с. [Nasonov EL, Nasonova VA. Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National Guide]. Moscow: GEOTAR-media; 2008. 290 p.]
2. Goldring SR. Inflammation-induced bone loss in the rheumatic diseases. In: Primer on metabolic bone disease and disorders of mineral metabolism. Hoboken: John Wiley and Sons, Inc.; 2009. Chapter 59.
3. Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol. 1996;35:309–22. DOI: http://dx.doi.org/10.1093/rheumatology/ 35.4.309.
4. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490–5. DOI: http://dx.doi.org/10.1001/jama.292.4.490.
5. Deodhar AA, Brabyn J, Pande I, et al. Hand bone densitometry in rheumatoid arthritis, a five year longitudinal study: an outcome measure and a prognostic marker. Ann Rheum Dis. 2003;62:767–70. DOI: http://dx.doi.org/10.1136/ard.62.8.767.
6. Celiker R, Gokce-Kutsal Y, Cindas A, et al. Osteoporosis in rheumatoid arthritis: effect of disease activity. Clin Rheumatol. 1995;14:429–33. DOI: http://dx.doi.org/10.1007/BF02207677.
7. Haugeberg G, Uhlig T, Flach JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Results from 394 patients in the Oslo country rheumatoid arthritis register. Arthritis Rheum. 2000;43:522–30. DOI: http://dx.doi.org/10.1002/1529-0131(200003)43:3<522::AIDANR7>3.0.CO;2-Y.
8. Kroger H, Honkanen R, Saarikoski S, Alhave E. Decreased axial BMD in perimenopausal women with rheumatoid arthritis – a population-based study. Ann Rheum Dis. 1994;53:18–23. DOI: http://dx.doi.org/10.1136/ard.53.1.18.
9. Cortet B, Guyot MH, Solau E, et al. Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol. 2000;18:683–90.
10. Eastgate JA, Wood NC, Di Giovine FS, et al. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet. 1988;340:706–9. DOI: http://dx.doi.org/10.1016/S0140-6736(88)90185-7.
11. Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol. 1995;22:1055–9.
12. Saario R, Sonninen P, Mottonen T, et al. Bone mineral density of the lumbar spine in patients with advanced rheumatoid arthritis: influence of functional capacity and corticosteroid use. Scand J Rheumatol. 1999;28:363–7. DOI: http://dx.doi.org/10.1080/03009749950155355.
13. Saag KG, Koehnke R, Caldwell JR, et al. Low dose longterm corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96(2):115–23. DOI: http://dx.doi.org/10.1016/0002-9343(94)90131-7.
14. Maricic M. Update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2011;37(3):415–31. DOI: http://dx.doi.org/10.1016/j.rdc.2011.07.00315.
15. Насонов ЕЛ, редактор. Ревматология: Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. [Nasonov EL, editor. Revmatologiya: Klinicheskie rekomendatsii [Rheumatology: Clinical recommendations]. Moscow: GEOTARMedia; 2010].
16. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs. Ann Rheum Dis. 2010;69;964–75. DOI: http://dx.doi.org/10.1136/ard.2009.126532.
17. Smolen JS, Aletaha D, Bijsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69;631–7. DOI: http://dx.doi.org/10.1136/ard.2009.123919.
18. Насонов ЕЛ, Самсонов МЮ. Новые направления исследования воспаления при ревматических заболеваниях. В кн.: Избранные лекции по клинической ревматологии. Под ред. В.А. Насоновой, Н.В. Бунчука. Москва: Медицина; 2001. 270 с. [Nasonov EL, Samsonov MYu. The new directions of research of an inflammation at rheumatic diseases. In: Izbrannye lektsii po klinicheskoi revmatologii [Chosen lectures on clinical rheumatology]. Nasonova VA, Bunchuk NV, editors. Moscow: Meditsina; 2001. 270 p.]
19. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? Arthritis Rheum. 2005;52(10):2975–2983. DOI: http://dx.doi.org/10.1002/art.21293.
20. Geusens PP, Landewe RB, Garnero P, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 2006;54(6):1772–7. DOI: http://dx.doi.org/10.1002/art.21896.
21. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156–63. DOI: http://dx.doi.org/10.1038/nm1538.
22. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106(12):1481–8. DOI: http://dx.doi.org/10.1172/JCI11176.
23. Fuller K, Murphy C, Kirstein B, et al. TNF-alpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology. 2002;143(3):1108–18.
24. Komine M, Kukita A, Kukita T, et al. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted ratbone marrow cell culture. Bone. 2001;28(5):474–83. DOI: http://dx.doi.org/10.1016/S8756-3282(01)00420-3.
25. Glantschnig H, Fisher JE, Wesolowski G, et al. M-CSF, TNFalpha and RANK ligand promote osteoclast urvival by signaling through mTOR/S6 kinase. Cell Death Differ. 2003;10(10):1165–77. DOI: http://dx.doi.org/10.1038/sj.cdd.4401285.
26. Gü ler-Yü ksel M, Bijsterbosch J, Goekoop-Ruiterman YP, et al. Changes in bonemineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis. 2008;67(6):823–8. DOI: http://dx.doi.org/10.1136/ard.2007.073817.
27. Eekman DA, Vis M, Bultink IE, et al. Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(2):389–90. DOI: http://dx.doi.org/10.1136/ard.2009.127787.
28. Marotte H, Pallot-Prades B, Grange L, et al. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther. 2007;9(3):R61. DOI: http://dx.doi.org/10.1186/ar2219.
29. Lange U, Teichmann J, Mü ller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford). 2005;44(12):1546–8. DOI: http://dx.doi.org/10.1093/rheumatology/kei082.
30. Haugeberg G, Conaghan PG, Quinn M, Emery P. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, doubleblind, placebocontrolled study. Ann Rheum Dis. 2009;68(12):1898–901. DOI: http://dx.doi.org/10.1136/ard.2008.106484.
31. Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1495–9. DOI: http://dx.doi.org/10.1136/ard.2005.044198.
32. Chopin F, Garnero P, le Henanff A, et al. Longterm effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(3):353–7. DOI: http://dx.doi.org/10.1136/ard.2007.076604.
33. Seriolo B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 2006;1069:420–7. DOI: http://dx.doi.org/10.1196/annals.1351.040.
34. Wijbrandts CA, Klaasen R, Dijkgraaf MGW, et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis. 2009;68:373–6. DOI: http://dx.doi.org/10.1136/ard.2008.091611.
35. Krieckaert CLM, Nurmohamed MT, Wolbink G, Lems WF. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford). 2013;Mar;52(3):547–53. DOI: http://dx.doi.org/10.1093/rheumatology/kes320.
36. Haugeberg G, Orstavik RE, Uhlig T, et al. Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years. Arthritis Rheum. 2002;46:1720–8. DOI: http://dx.doi.org/10.1002/art.10408.
37. Hoff M, Kvien TK, Kalvesten J, et al. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis. 2009;68:1171–6. DOI: http://dx.doi.org/10.1136/ard.2008.091264.
38. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab.2011;86:2032–42.
39. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–34. DOI: http://dx.doi.org/10.1001/jama.286.3.327.
40. Koukkunen H, Penttila K, Kemppainen A, et al. C-Reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina ectoris. Ann Med. 2001;33:37–47. DOI: http://dx.doi.org/10.3109/0785389010900205841.
41. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417–24. DOI: http://dx.doi.org/10.1056/NEJM199408183310701.
42. Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int. 2010;21:1287–93. DOI: http://dx.doi.org/10.1007/s00198-010-1192-7.
43. Ohsugi Y, Kishimoto T. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2008;8:669–81. DOI: http://dx.doi.org/10.1517/14712598.8.5.669.
44. Maini RN, Taylor PC, Szechinski J, et al.; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29. DOI: http://dx.doi.org/10.1002/art.22033.
45. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7. DOI:
46. http://dx.doi.org/10.1136/ard.2006.068064.
47. Smolen JS, Beaulieu A, Rubbert-Roth A, et al.; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo controlled, randomised trial. Lancet. 2008;371:987–97. DOI: http://dx.doi.org/10.1016/S0140- 6736(08)60453-5.
48. Terpos E, Fragiadaki K, Konsta M, et al. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol. 2011;29:921–5.
49. Kume K, Amano K, Yamada S, et al. The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis. Rheumatology (Oxford). 2014.
50. Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 549 c. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological preparations in treatment f rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. 549 p.]
51. Fardellone P, Sejourne A, Paccou J, Goeb V. Bone remodeling markers in rheumatoid arthritis. Mediators Inflamm. 2014;2014:484280. DOI: http://dx.doi.org/10.1155/2014/484280.
52. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–806. DOI: http://dx.doi.org/10.1002/art.22025.
53. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose ranging trial. Arthritis Rheum. 2006;54:1390–400. DOI: http://dx.doi.org/10.1002/art.21778.
54. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebocontrolled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629–35. DOI: http://dx.doi.org/10.1136/ard.2009.119933.
55. Mease PJ, Cohen S, Gaylis NB, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol. 2010;37:917–27. DOI: http://dx.doi.org/10.3899/jrheum.090442.
56. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683–93. DOI: http://dx.doi.org/10.1093/rheumatology/keq116.
57. Boumans MJH, Thurlings RM, Yeo L, et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis. 2012;71:108–13. DOI: http://dx.doi.org/10.1136/annrheumdis-2011-200198.
58. Hein G, Eidner T, Oelzner P, et al. Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study. Rheumatol Int. 2011;31(2):269–72. DOI: http://dx.doi.org/10.1007/s00296-010-1560-9.
59. Wheater G, Hogan VE, Teng YKO, et al. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. Osteoporos Int. 2011;22:3067–72. DOI: http://dx.doi.org/10.1007/s00198-011-1607-0.
60. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155–92. DOI: http://dx.doi.org/10.1210/er.2007-0014.
61. Cohen SB, Dore RK, Lane NE, et al. Denosumab Treatment Effects on Structural Damage, Bone Mineral Density, and Bone Turnover in Rheumatoid Arthritis. A 12-month, multicenter, randomized, double-blind, placebo-controlled, phase ii clinical trial. Arthritis Rheum. 2008;58:1299–309. DOI: http://dx.doi.org/10.1002/art.23417.
62. Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with RA receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010;69:872–5. DOI: http://dx.doi.org/10.1136/ard.2009.112920.
63. Deodhar AA, Dore RK, Mandel D, et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res. 2010;62:569–74. DOI: ttp://dx.doi.org/10.1002/acr.20004.
64. Deodhar AA, Brabyn J, Pande I, et al. Hand bone densitometry in rheumatoid arthritis, a five year longitudinal study: an outcome measure and a prognostic marker. Ann Rheum Dis. 2003;62:767–70. DOI: http://dx.doi.org/10.1136/ard.62.8.767.
65. Sharp JT, Wayne T, Ory P, et al. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res. 2010;62:537–44. DOI: http://dx.doi.org/10.1002/acr.20172.
66. Takeuchi T. Dose-response effects of denosumab, a novel subcutaneous RANKL inhibitor, on the progression of bone erosion in japanese patients with rheumatoid arthritis treated with methotrexate: results of phase II DRIVE Study-A twelve month placebo controlled, randomized, double blind study. Arthritis Rheum. 2013;65:S1198.
67. Kanamaru F, Iwai H, Ikeda T, et al. Expression of membranebound and soluble receptor activator of NF kappa B ligand (RANKL) in human T cells. Immunol Lett. 2004;93:239–46. DOI: http://dx.doi.org/10.1016/j.imlet.2004.05.010.
68. Nakashima T, Takayanagi H. Osteoclast and the immune system. J Bone Mineral Metab. 2009;27:519–29. DOI: http://dx.doi.org/10.1007/s00774-009-0089-z.
69. Li Y, Toraldo G, Li A, et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood. 2007;109:3839–48. DOI:http://dx.doi.org/10.1182/blood- 2006-07-037994.
70. Ott SM. Sclerostin and wnt signaling – the pathway to bone strength. J Clin Endocrin Metabol. 2005;90:6741–3. DOI: http://dx.doi.org/10.1210/jc.2005-2370.
71. Veverka V, Henry AJ, Slocombe BM, et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem. 2009;284:10890–1000. DOI: http://dx.doi.org/10.1074/jbc.M807994200.
72. Sambrook P. Tumour necrosis factor blockade and the risk of osteoporosis: back to the future. Arthritis Res Ther. 2007;9:1079. DOI: http://dx.doi.org/10.1186/ar2277.
73. Garnero P, Thompson E, Woodwork T, Smolen JS. Rapid and sustained improvement of bone and cartilage turnover markers with the anti-interleukin receptor inhibitor tocilizumab plus methotrexate in patients with inadaequate response to methotrexate: Results from a substudy of the multicenter double blind, placebo controlled trial of tocilizumab in inadaequate responders to methotrexate alone. Arthritis Rheum. 2010;62:33–43. DOI: http://dx.doi.org/10.1002/art.25053.
Review
For citations:
Dydykina P.S., Dydykina I.S., Nasonov E.L. IMPACT OF BIOLOGICAL THERAPY ON BONE IN PATIENTS WITH RHEUMATOID ARTHRITIS. Rheumatology Science and Practice. 2014;52(6):669-677. (In Russ.) https://doi.org/10.14412/1995-4484-2014-669-677
Views:
1223
Email this article 